logo_ProQR-150x150.png
ProQR Announces First Quarter 2021 Operating and Financial Results
May 06, 2021 07:00 ET | ProQR Therapeutics N.V.
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022Positive data reported from the Phase 1/2 clinical trial of QR-421a for the...
logo_ProQR-150x150.png
ProQR Announces Participation in Upcoming Kempen Life Sciences Conference
April 22, 2021 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Annual Meeting of Shareholders
April 20, 2021 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
March 30, 2021 22:25 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA...
logo_ProQR-150x150.png
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference
December 18, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference
November 18, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Third Quarter 2020 Operating and Financial Results
November 16, 2020 07:00 ET | ProQR Therapeutics N.V.
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021Enrollment completed for QR-421a...
logo_ProQR-150x150.png
ProQR to Participate in Upcoming Investor Conferences
September 03, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Second Quarter 2020 Operating and Financial Results
August 06, 2020 16:30 ET | ProQR Therapeutics N.V.
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;Strategic...
logo_ProQR-150x150.png
ProQR Announces Expert Perspectives Conference Call Series
June 12, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...